News
-
-
PRESS RELEASE
Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
Tharimmune, Inc. completes first patient dosing in Phase 1 clinical trial for TH104, an oral thin film targeting liver-related and pruritogenic inflammatory conditions. Topline data expected in 2Q24 with full readout shortly after. Company fully funded into 2025 for Phase 1 and 2 readouts -
PRESS RELEASE
Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update
Tharimmune, Inc. initiates Phase 1 trial for TH104, a buccal film with nalmefene for liver-related pruritogenic inflammatory conditions. Phase 2 planning for PBC, near-clinical pipeline and R&D day planned. Company fully funded into 2025 -
-